HAEMONETICS CORP — Director's Dealing 2017

Nov 15, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2016-10-25

Reporting Person: Goldstein Dan (Chief Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-10-25	Common Stock	A	1350	—	Acquired	3747	Direct
2017-06-06	Common Stock	A	1080	—	Acquired	4827	Direct
2017-11-13	Common Stock	M	2607	$34.42	Acquired	7434	Direct
2017-11-13	Common Stock	M	1456	$34.21	Acquired	8890	Direct
2017-11-13	Common Stock	S	2607	$54.945	Disposed	6283	Direct
2017-11-13	Common Stock	S	300	$54.921	Disposed	5983	Direct
2017-11-13	Common Stock	S	200	$54.94	Disposed	5783	Direct
2017-11-13	Common Stock	S	956	$54.957	Disposed	4827	Direct
2017-11-13	Common Stock	S	560	$54.841	Disposed	4267	Direct
2017-11-13	Common Stock	S	68	$54.886	Disposed	4199	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-10-25	Non-qualified Stock Option (Right to Buy)	$34.21	A	5826	Acquired	2023-10-25	Common Stock (5826)	Direct
2017-06-06	Non-qualified Stock Option (Right to Buy)	$41.64	A	4426	Acquired	2024-06-06	Common Stock (4426)	Direct
2017-11-13	Non-qualified Stock Option (Right to Buy)	$34.42	M	2607	Disposed	2023-04-06	Common Stock (2607)	Direct
2017-11-13	Non-qualified Stock Option (Right to Buy)	$34.21	M	1456	Disposed	2023-10-25	Common Stock (1456)	Direct

Footnotes

F1: Restricted Stock Units which vest 25% per year over 4 years following the grant date.

F2: Non-qualified stock option grant providing a right to buy shares of common stock exercisable in annual increments of 25% beginning on the first anniversary of the date of grant.